Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy

被引:31
作者
Turpie, AGG [1 ]
机构
[1] Gen Hosp, Hamilton Hlth Sci, Dept Med, Hamilton, ON L8L 2X2, Canada
关键词
antithrombotic; fondaparinux; low-molecular-weight heparin; pentasaccharide; thromboprophylaxis; venous diromboembolism;
D O I
10.1517/14656566.5.6.1373
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fondaparinux (Arixtra(R)) is the first of a new class of antithrombotic compounds - Factor Xa inhibitors. This synthetic pentasaccharide acts by inhibiting Factor Xa selectively. its efficacy and safety have been demonstrated in animal models of venous and arterial thromboses and bleeding risk. In humans, its pharmacokinetic profile after subcutaneous injection shows a rapid onset of antithrombotic activity and an elimination half-life that reliably allows once-daily dosing. As the inter-subject variability is limited, no laboratory monitoring of coagulation parameters is needed. The efficacy and safety of fondaparinux have been examined in several Phase II and III clinical trials. So far, the largest programme has involved - 9000 patients undergoing major orthopaedic surgery of the lower limbs. In the setting of short-term prophylaxis, the efficacy of fondaparinux for preventing venous thromboembolism was significantly superior to that of the low-molecular-weight heparin, enoxaparin (common reduction in risk: 50.6%; p < 0.001). The benefit of extended thromboprophylaxis with fondaparinux in hip fracture surgery patients was also demonstrated. Fondaparinux also showed benefit in the prevention of venous thromboembolism in other surgical and medical settings and in the treatment of patients with venous thromboembolism. Overall, fondaparinux therapy was as well-tolerated as currently available treatments. In conclusion, selective inhibition of Factor Xa is an effective antithrombotic strategy. Fondaparinux may substantially improve the prevention and treatment of thrombosis. Fondaparinux 2.5 mg once-daily s.c. has been approved for the prevention of venous thromboembolism after major orthopaedic surgery. Fondaparinux use in extended prophylaxis (4 weeks) after hip fracture surgery has also been recently approved.
引用
收藏
页码:1373 / 1384
页数:12
相关论文
共 55 条
[1]  
Agnelli G, 2003, BLOOD, V102, p15A
[2]   Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies [J].
Ahmad, S ;
Jeske, WP ;
Walenga, JM ;
Hoppensteadt, DA ;
Wood, JJ ;
Herbert, JM ;
Messmore, HL ;
Fareed, J .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1999, 5 (04) :259-266
[3]   Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia [J].
Amiral, J ;
Lormeau, JC ;
MarfaingKoka, A ;
Vissac, AM ;
Wolf, M ;
BoyerNeumann, C ;
Tardy, B ;
Herbert, JM ;
Meyer, D .
BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 (02) :114-117
[4]   Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. [J].
Bauer, KA ;
Eriksson, BI ;
Lassen, MR ;
Turpie, AGG .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (18) :1305-1310
[5]  
BEGUIN S, 1989, THROMB HAEMOSTASIS, V61, P397
[6]   Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers [J].
Bijsterveld, NR ;
Moons, AH ;
Boekholdt, SM ;
van Aken, BE ;
Fennema, H ;
Peters, RJG ;
Meijers, JCM ;
Büller, HR ;
Levi, M .
CIRCULATION, 2002, 106 (20) :2550-2554
[7]  
Boneu B, 1995, THROMB HAEMOSTASIS, V74, P1468
[8]  
Büller HR, 2000, CIRCULATION, V102, P2726
[9]  
Büller HR, 2003, NEW ENGL J MED, V349, P1695
[10]  
CADROY Y, 1993, THROMB HAEMOSTASIS, V70, P631